Phrontline Biopharma

Phrontline Biopharma was founded in early 2022, firmly committed to innovating at the source of ADC drugs. Its proprietary technology platform covers the four core technologies of ADC drugs (payload, linker, conjugation method, antibody), rapidly establishing advanced antibody discovery and bispecific antibody preparation platforms, a Linker-Payload design and synthesis platform, and a site-specific and stoichiometric conjugation technology platform.